StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: NA (inferred Swing (≤2wk))28 Sept 2026via NDTV Profit (Live)

Entry₹1,210.7Inferred
Target₹1,455
Total upside +20.18% (call closed)
Stop loss₹1,079-10.88% risk
At expiry₹1,134.412 Oct 2026, 3:30 pm
Expired-6.30%auction close
Follow Sachin Janardan Sarvade for new calls(15% target hit, 94 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 12 Oct 2026
6 supporting2 neutral0 opposing
Supports the BUY call (6)

Zydus Lifesciences and MSN have partnered to launch the first generic version of Adempas (Riociguat tablets) in the U.S. market.

BSE · Company Update·5 Oct · 6d ago

(opens in new tab)

The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.

BSE · Company Update·28 Sept · 2w ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·29 Sept · 2w ago

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · 2w ago

(opens in new tab)

The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.

BSE · Company Update·26 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 2w ago

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Every call and its outcome